MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Tenofovir exalidex

CAS No. : 911208-73-6

MCE 国际站：Tenofovir exalidex

产品活性：Tenofovir exalidex (CMX157) 是一种非环核苷酸类似物 Tenofovir 的脂质结合物，对野生型和抗逆转录病毒耐药的 HIV 毒株，包括多药核苷/核苷酸类似物耐药病毒，都有活性。Tenofovir exalidex 对人外周血单个核细胞中所有主要的HIV-1和HIV-2亚型以及单核细胞来源的巨噬细胞中所有 HIV-1 菌株具有活性，EC₅₀ 范围在 0.2 和 7.2 nM 之间。Tenofovir exalidex 具有口服活性，无明显毒性。Tenofovir exalidex 对 HBV 也有活性。

研究领域：Anti-infection  |  Cell Cycle/DNA Damage

作用靶点：HIV  |  HBV  |  Nucleoside Antimetabolite/Analog

In Vitro: Tenofovir exalidex is consistently >300-fold more active than Tenofovir against multiple viruses in several different cell systems. Tenofovir exalidex will be effective against MNR mutants, including those that are unresponsive to all currently available NRTIs. Notably, the average EC₅₀ in PBMCs for CMX157 against a panel of 27 wild-type HIV-1 isolates representing group M subtypes A to G and group O was 2.6 nM (range, 0.2 to 7.2 nM).
Tenofovir exalidex exerts its therapeutic actions by inhibiting HBV polymerase-mediated HBV DNA elongation, but there is no known binding of cyclophilins to HBV polymerase nor participation of cyclophilins in DNA elongation. The combinational effect of CRV431 (host-targeting) and Tenofovir exalidex (direct-acting) on HBV DNA production is more consistent with the two compounds acting on distinct steps of the HBV life cycle.

In Vivo: Tenofovir exalidex (Sprague-Dawley rats) is orally available and has no apparent toxicity when given orally to rats for 7 days at doses of 10, 30, or 100 mg/kg/day.Tenofovir exalidex (5-10 mg/kg; oral gavage; daily for a period of 16 days) decreases liver HBV DNA levels dose-dependently.

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  Cell Cycle/DNA Damage Compound Library  |  Clinical Compound Library  |  Antiviral Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Reprogramming Compound Library  |  Lipid Compound Library  |  Orally Active Compound Library  |  Anti-Lung Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Anti-Cancer Metabolism Compound Library  |  Rare Diseases Drug Library  |  2’-dG (iBu)-2’-phosphoramidite  |  Peldesine dihydrochloride  |  3’-Beta-C-Methyl-N6-(m-trifluoromethylbenzyl)adenosine  |  IBU-DC Phosphoramidite  |  8-Methylguanosine  |  Abacavir sulfate  |  2'-Deoxy-8-methylamino-adenosine  |  N6-Isopentenyl-2’-deoxy adenosine, 2’-deoxy riboprine  |  HIV-IN-6  |  7-Ethyl-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl)guanine  |  Epicoccone B  |  5’-Deoxy-5’-N-methylaminothymidine  |  N-Acetyl-2′-deoxycytidine  |  5-Carboxymethylaminomethyluridine  |  3-Deoxy-1,2-O-isopropylidene-5-p-toluoyl-a-D-glycero-pent-3-enofuranose  |  3,5-Di-O-benzoyl-2-deoxy-2-fluoro-5-trifluoromethyl-arabinouridine  |  Ditiocarb  |  6-Mercaptopurine-¹³C₂,¹⁵N  |  4′,5′-Didehydro-5′-deoxyadenosine  |  2’,3’,5’-Tri-O-acetyl-5,N3-dimethyluridine  |  2’-Deoxy-2’-fluoro-N1-methyluridine  |  5'-Homocytidine  |  2'-Deoxypseudoisocytidine  |  3’-O-DMT-N2-isobutyryl-2’-O-(2-methoxyethyl)guanosine  |  5’-Deoxy-5’-iodo-2’-O-(2-methoxyethyl)-5-methyluridine  |  Nevirapine  |  DAPTA  |  Aloperine  |  Elipovimab  |  3’,5’-Di-O-benzoyl-2’-deoxy-2’-fluoro-5-methyl-β-D-arabino-uridine

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

货号: HY-109014

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。